News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Medway setup a state-of-the-art Heart Institute in Chennai
Total transaction value of the divestment is Rs. 3,660 million
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Six engaging sessions focusing on Prevention of Kidney Diseases, Brain Stem Death Declaration, Deceased Donor Management, Prevention of Liver Diseases, Legal Aspects of Organ and Tissue Donation, Eye Donation and Corneal Transplant held as part of the Webinar
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Women of all ages will get round-the-clock access to comprehensive treatment
Subscribe To Our Newsletter & Stay Updated
